Last update:

Oncology & Cancer

Immunotherapy boosts survival of advanced Hodgkin lymphoma in clinical trial

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...

Diseases, Conditions, Syndromes

COVID study reveals virus-induced inflammation during pregnancy, redefines vertical transmission

A new Cleveland Clinic-led study published in The EMBO Journal shows that mild and asymptomatic SARS-CoV-2 infections can trigger immune responses in a pregnant individual that may cause serious inflammatory responses in ...

Medical research news

Oncology & Cancer

Team identifies origin of deadly ovarian cancer

Researchers have identified the origin of ovarian cancer that develops in the fallopian tube, which opens doors to discovering new methods for diagnosing the disease and potential therapies.

Medications

Which clot-busting drug is tied to better recovery after stroke?

For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later than the drug alteplase, ...

Immunology

How the immune system learns from harmless particles

Our lungs are bombarded by all manner of different particles every single day. While some are perfectly safe for us, others—known as pathogens—have the potential to make us ill. The immune system trains its response whenever ...

Genetics

Gene linked to epilepsy and autism decoded in new study

A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder, and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, ...

Oncology & Cancer

Blocking gene may halt growth of breast cancer cells

Shutting down a gene called PRMT5 stopped metastatic estrogen receptor-positive (ER+) breast cancer cells from growing after they acquired resistance to a standard therapy known as CDK4/6 inhibitors, UT Southwestern Medical ...